HKMPF News and Press, Hikma Pharmaceuticals Plc From 02/26/23

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q4 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q4 - Results - Earnings Call Presentation

Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 A.M. ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Chief Executive Officer Brian Hoffmann - President of Generics Riad Mis...

Hikma Pharmaceuticals press release ( OTCPK:HKMPF ): FY GAAP EPS of $1.81. Revenue of $2.52B (-1.2% Y/Y). 2023 Outlook: Injectables revenue growth in the range of 7% to 9%, with core operating margin in the range of 36% to 37% Branded revenue growth in the mid to high-sing...

Hikma Pharmaceuticals Plc. (HKMPF) 2022 Interim Results August 04, 2022 05:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants Presentation Said Darwazah Hello everyo...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2022 Q2 earnings call. For further details see: Hikma Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation

Hikma Pharmaceuticals press release ( OTCPK:HKMPF ): 1H GAAP EPS of $76.20. Revenue of $1.21B (flat Y/Y) misses by $10M . Outlook for full year 2022: Injectables – we continue to expect revenue growth to be in the mid to high-single digits and core operating...

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Canada NewsWire LONDON , April 29, 2022 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary ...

Update: Opiant Pharmaceuticals (NASDAQ:OPNT) has advised readers to disregard the news release issued via PR Newswire on Thursday about the purported licensing deal to market the company’s opioid overdose therapy OPNT003 in the EU and U.K. “This release contains incorrect inform...

Santa Monica, California-based Opiant Pharmaceuticals (NASDAQ:OPNT) has entered into a licensing deal with U.K.-based rival, Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) for OPNT003, an experimental therapy targeted at Opioid overdose, the companies announced on Friday. Per the terms of ...

Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) said it received preliminary approval from the U.S. Federal Trade Commission for its its acquisition of Custopharm from Water Street Healthcare Partners. The company said the parties have now obtained all regulatory approvals require...